RCM Strategy Shifts to Proactive Denial Prevention
A growing trend in RCM is the shift from managing denials to proactively preventing them through tactics like eligibility verification and ensuring clean claim rates, according to industry discussions. This focus on pre-submission audits and true ROI calculation frameworks is gaining traction as a way to reduce AR days and improve efficiency.
The financial stakes of claim denials are staggering, with over $262 billion in claims initially denied for U.S. hospitals in one year. Rising denial rates, which now average over 10% for hospitals, represent a significant drain on resources and a direct hit to net patient revenue. Beyond lost revenue, the administrative burden is immense. The cost to rework a single denied claim averages $25 for practices and can be as high as $181 for hospitals. Compounding the issue, up to 65% of denied claims are never corrected and resubmitted, turning preventable errors into permanent revenue loss. The vast majority of denials, between 86% and 90%, are considered preventable. They most often stem from front-end process failures, with missing or inaccurate patient information being the leading cause, followed by issues with prior authorization and insurance eligibility. This high rate of preventability is driving the "shift-left" strategy, which focuses on catching errors before a claim is ever submitted. By leveraging data analytics from past denials, revenue cycle teams can identify patterns and deploy rules-based claim scrubbing to flag high-risk submissions proactively. Automating front-end processes is a cornerstone of modern denial prevention. Implementing real-time, automated insurance eligibility verification can reduce eligibility-related denials by 60-80% and accelerate reimbursements by up to 50%. Leading organizations track specific Key Performance Indicators (KPIs) to monitor the health of their revenue cycle. A primary goal is to achieve a Clean Claim Rate (the percentage of claims paid on the first submission) of 90% or higher, while keeping the Initial Denial Rate below 5%.
